Cancer cells have evolved a sophisticated dual-defense system that simultaneously repairs their own DNA damage while silencing the immune system's ability to detect and eliminate them. This discovery could explain why certain lung cancers resist both chemotherapy and immunotherapy treatments that should theoretically work.
Researchers identified BRIP1, a protein from the Fanconi anemia repair pathway, as the master coordinator of this two-pronged resistance mechanism in lung adenocarcinoma. Elevated BRIP1 levels correlate with advanced disease stages and worse patient outcomes. The protein orchestrates enhanced homologous recombination repair by acetylating RINT1 at lysine 728, strengthening critical protein interactions within the MRE11-RAD50-NBS1 repair complex. Simultaneously, BRIP1 activates NF-κB signaling through interaction with RNA demethylase ALKBH5, driving PD-L1 expression and promoting metastasis.
This dual mechanism creates what researchers term an 'immune-cold' tumor environment—one enriched with immunosuppressive regulatory T-cells while excluding cancer-fighting cytotoxic T-cells. The enhanced DNA repair prevents damaged genetic material from accumulating in the cytoplasm, where it would normally trigger cGAS-STING innate immune pathways that alert the immune system to the cancer's presence. This represents a fundamental shift in understanding cancer resistance, revealing how DNA repair and immune evasion are not separate processes but interconnected survival strategies. The finding suggests that targeting BRIP1 could potentially restore both chemotherapy sensitivity and immune recognition, offering a dual therapeutic approach for treatment-resistant lung adenocarcinomas.